The UK Transplantation Clinical Study Group and the James Lind Alliance Transplant Priority Setting Partnership highlighted the need for more research on renal transplant rejection.
This idea aligned with a clinical trial early in design to assess the efficacy of available treatments for acute antibody-mediated rejection (aAMR) in renal transplantation. The trial is still in set-up phase, but will be a UK multi-centre randomised controlled trial. Funding has been provided by the Kidney Research UK and the NIHR Health Technology Assessment Programme. Dr Michelle Willicombe, Imperial College London, is Chief Investigator.